A9543 Y90 ibritumomab, prescription
Also known as: Zevalin therapeutic, Y-90 ibritumomab
Yttrium Y-90 ibritumomab tiuxetan injection used therapeutically for treatment of B-cell lymphomas.
In Plain Language
radioactive lymphoma treatment; cancer therapy
Clinical Context
Used in targeted radiotherapy for treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
RVU Information
CPT A9543 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
HCPCS A-codes cover medical supplies, equipment, and transport services. Documentation must establish medical necessity and include a physician order. For durable medical equipment (DME), a Certificate of Medical Necessity (CMN) or detailed written order may be required.
Specialties
Frequently Asked Questions
What is CPT code A9543?
CPT A9543 (Y90 ibritumomab, prescription) is a A Codes code. Yttrium Y-90 ibritumomab tiuxetan injection used therapeutically for treatment of B-cell lymphomas.
Does Medicare cover A9543?
Medicare coverage for A9543 depends on medical necessity and applicable Local Coverage Determinations (LCDs). Used in targeted radiotherapy for treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. A physician order is typically required.
When is CPT A9543 used?
Used in targeted radiotherapy for treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.